22 participants
Durvalumab and Oleclumab in Resectable PDAC
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-06-23
- Start Date:
- 2023-11-29
- Completion:
- 2026-10-30
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
- DRUG
No Results Yet